AADI BIOSCIENCE INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect three Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal: Anupam Dalal, M.D.

AADI BIOSCIENCE INC.’s own tally for this item (“Elect Director: Anupam Dalal, M.D.”): 18,532,860 for, 5,029,089 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 818,629 for, 285,873 withheld, 5,917 abstained.

Description as filed by funds: To elect three Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal: David Lennon, Ph.D.

AADI BIOSCIENCE INC.’s own tally for this item (“Elect Director: David Lennon, Ph.D.”): 19,378,308 for, 4,183,641 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 1,092,301 for, 12,201 withheld, 5,917 abstained.

Description as filed by funds: To elect three Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal: Mohammad Hirmand, M.D.

AADI BIOSCIENCE INC.’s own tally for this item (“Elect Director: Mohammad Hirmand, M.D.”): 19,402,347 for, 4,159,602 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 1,092,301 for, 12,201 withheld, 5,917 abstained.

Description as filed by funds: The PIPE Financing Proposal. To approve, for purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the issuance of an aggregate of 21,592,000 shares of Aadi's common stock, par value $0.0001 per share, at a price of $2.40 per share and pre-funded warrants to purchase up to an aggregate of 20,076,500 shares of Aadi's common stock at a purchase price of $2.3999 per pre-funded warrant.

AADI BIOSCIENCE INC.’s own tally for this item (“2. The PIPE Financing Proposal”): 12,898,905 for, 7,202,353 against, per its Form 8-K filed March 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 754,246 for, 535,976 against.

Description as filed by funds: Adjournment Proposal. To approve the adjournment of the Special Meeting, if necessary and to the extent permitted by the Divestiture Agreement, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Divestiture Proposal.

AADI BIOSCIENCE INC.’s own tally for this item (“5. Approval of one or more adjournments of this meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the meeting to approve the Divestiture Proposal (the " Ad”): 15,121,060 for, 4,948,986 against, per its Form 8-K filed March 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 1,063,305 for, 226,917 against.

Description as filed by funds: Divestiture Proposal. To approve the sale by Aadi to KAKEN INVESTMENTS INC. of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. and thereby all or substantially all of Aadi's assets related to its FYARRO(R) (sirolimus protein-bound particles for injectable suspension) (albumin-bound) program, pursuant to the terms of a stock purchase agreement, dated December 19, 2024, as it may be amended from time to time, which may be deemed to be a sale of substantially all of Aadi's assets under Section 271 of the Delaware General Corporation Law, as amended.

AADI BIOSCIENCE INC.’s own tally for this item (“1. Approval of the sale by the Company to KAKEN INVESTMENTS INC. of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. and thereby all or substantially all of the Company's assets related to its FYA”): 16,606,498 for, 3,495,206 against — passed, per its Form 8-K filed March 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 5.07 below, at the Special Meeting, the Company's stockholders approved the amendment and restatement of the Company's 2021 Equity Incentive Plan (the " 2021 Plan ") to (i) increase the number of shares available for future grant under the 2021 Plan from 2,000,284 shares to 8,300,284 shares an…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a supermajority of the shares outstanding (“81.41% of the voting power”).

The 12 asset managers below reported 1,290,888 for.

Description as filed by funds: Equity Plan Increase Proposal. To approve an amendment to the Aadi Bioscience, Inc. 2021 Equity Incentive (the "2021 Plan") to (i) increase the shares available for issuance under the 2021 Plan by 6,300,000 shares from 2,000,284 shares to 8,300,284 shares and (ii) increase the 2021 Plan's default annual automatic share reserve increase occurring on January 1 of each year from 4% of outstanding shares on the last day of the immediately preceding fiscal year to 5%.

AADI BIOSCIENCE INC.’s own tally for this item (“3. The Equity Plan Increase Proposal”): 11,863,025 for, 8,234,637 against, per its Form 8-K filed March 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 59% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 12 asset managers below reported 1,290,888 against.

Description as filed by funds: Non-Binding Advisory Vote on Golden Parachutes Proposal. To approve, on a non-binding, advisory basis, certain compensation that will or may become payable to our named executive officers in connection with the Divestiture.

AADI BIOSCIENCE INC.’s own tally for this item (“4. Approval of, on a non-binding, advisory basis, certain compensation that will or may become payable to the Company's named executive officers in connection with the Divestiture (the " Golden Parachutes Proposal "); an”): 15,490,810 for, 4,598,457 against, per its Form 8-K filed March 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 11 managers: 1,290,222 for.

Institutional-manager reports, all 41 managers: 9,663,427 for. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.

AADI BIOSCIENCE INC.’s own tally for this item (“2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the Proxy Statement”): 18,855,748 for, 4,692,033 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 10 managers: 819,429 for, 290,990 against.

Institutional-manager reports, all 37 managers: 10,173,188 for, 346,208 against. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

AADI BIOSCIENCE INC.’s own tally for this item (“3. Ratification of the appointment of BDO USA, P.C”): 28,065,323 for, 524,039 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 1,110,419 for.